SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)

Introduction: Teprotumumab treatment resulted in statistically and clinically meaningful improvements across multiple facets of active TED and was generally well-tolerated in Phase 2 and 3 trials.(1,2) An initial intravenous infusion of 10 mg/kg followed by 20 mg/kg every 3 weeks was selected based...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Xin, Yan, Xu, Fengyan, Gao, Yuying, Bhatt, Nivedita, Chamberlain, Jason, Kovalenko, Maria, Sile, Saba, Sun, Rui, Holt, Robert, Ramanathan, Srini
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Thyroid
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207720/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1047
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares